Health care stocks were flat to higher premarket Tuesday with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) recently inactive.
Novo Nordisk's (NVO) weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported, citing senior company officials. Shares of Novo Nordisk were over 3% higher pre-bell.
NeurAxis (NRXS) shares surged past 160% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device for treating functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
Zymeworks (ZYME) shares were up over 1% after the company said new preclinical data on its experimental respiratory inflammation drug ZW1528 has shown positive results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.